Latest Breaking News On - Ashfield medcomms - Page 1 : comparemela.com

Hotter Temperatures May Heighten Headaches in Migraine Sufferers

As temperatures rise, so do chances for migraine attacks, according to a new study from a team of researchers at the University of Cincinnati College

Only Four Weeks Until Creative Tech Europe 2024: A Gathering of Creative Technologists in London

There are just four weeks to go until creative production leaders, technologists, and decision-makers in brands, agencies, and other industry players

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial

GALLANT-1: GB1211 Galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) -October 23, 2023 at 08:28 am EDT

GALLANT-1: GB1211 Galectin-3 inhibitor plus atezolizumab for first line treatment in patients .

MM+M reveals its 2023 Awards finalists

The medical marketing industry’s biggest night of the year is scheduled for October 5 at Cipriani Wall Street.